Medical Device | May 18, 2022
Singapore based Inspired Technology receives WHO certification
The latest certification endorses product for cold chain monitoring across 194 WHO member countries
The latest certification endorses product for cold chain monitoring across 194 WHO member countries
Candle Partners, an investment banking & advisory service for M&A among others, has closed many deals in the healthcare space. Ankit Poddar, Director, Candle Partners spoke to Thomas C Thottathil, Editor, Indianpharmapost.com about the prospects for the industry.
The companies expect to complete the submission of the NDA for treatment of MDD in the second half of 2022; associated filing for postpartum depression is anticipated in the first half of 2023
All the capex is being met through internal accruals only
Momelotinib complements GSK’s existing expertise in haematology, with Sierra Oncology anticipating US regulatory submission in Q2 this year and EU submission in the second half of 2022
The expansion positions Cambrex with the largest and most advanced API facility in the United States
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
The new facility is scheduled to start operation in the first half of 2024
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
Supply increase to help meet growing global demand
Subscribe To Our Newsletter & Stay Updated
